Zobrazeno 1 - 10
of 353
pro vyhledávání: '"Suzanne, George"'
Autor:
Howard Streicher, Sandra P D'Angelo, Gary K Schwartz, Suzanne George, James L Chen, Cristina R Antonescu, Allison L Richards, Mohammed M Milhem, Nathan D Seligson, Austin C Goodrich, Brian A Van Tine, Jordan D Campbell, David A Liebner, William D Tap
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Background In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and provide a multi-omic correlative analysis
Externí odkaz:
https://doaj.org/article/941ae913983049cc9a3aa2fd82cc1c48
Autor:
Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1532-1539 (2023)
Abstract Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm,
Externí odkaz:
https://doaj.org/article/124378635bd247fb9b2242a52cc12063
Autor:
Patrick Schöffski, Suzanne George, Michael C. Heinrich, John R. Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ f
Externí odkaz:
https://doaj.org/article/9bb5658e944d433ba93df74a037e4505
Autor:
Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli, Suzanne George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). Method
Externí odkaz:
https://doaj.org/article/5ef7a369210841e8b9c3de8ba44e13d2
Autor:
Joshua B. B. Garfield, Hugh Piercy, Shalini Arunogiri, Dan I. Lubman, Samuel C. Campbell, Paul G. Sanfilippo, Jeff Gavin, Malcolm Hopwood, Eli Kotler, Suzanne George, Goke Okedara, Lara R. Piccoli, Victoria Manning
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Globally, methamphetamine use has increased in prevalence in recent years. In Australia, there has been a dramatic increase in numbers of people seeking treatment, including residential rehabilitation, for methamphetamine use diso
Externí odkaz:
https://doaj.org/article/2190ff7c957d4847b42031b6036d9451
Autor:
César Serrano, Ana Vivancos, Antonio López-Pousa, Judit Matito, Francesco M. Mancuso, Claudia Valverde, Sergi Quiroga, Stefania Landolfi, Sandra Castro, Cristina Dopazo, Ana Sebio, Anna C. Virgili, María M. Menso, Javier Martín-Broto, Miriam Sansó, Alfonso García-Valverde, Jordi Rosell, Jonathan A. Fletcher, Suzanne George, Joan Carles, Joaquín Arribas
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations af
Externí odkaz:
https://doaj.org/article/9f289e7391be4b1faf8ff1a0d9f5ce87
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine kinase inhibitor (TKI), meaningfully improved the treatment of adv
Externí odkaz:
https://doaj.org/article/0096071c03c444cfb1e0dd1774f7cde3
Autor:
Joseph M. Unger, Michael LeBlanc, Suzanne George, Norman Wolmark, Walter J. Curran, Peter J. O'Dwyer, Mitchell D. Schnall, Robert S. Mannel, Sumithra J. Mandrekar, Robert J. Gray, Fengmin Zhao, Mariama Bah, Riha Vaidya, Charles D. Blanke
Publikováno v:
Journal of Clinical Oncology. 41:2020-2028
PURPOSE In the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all adult network group trials has never been syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd04723984d939b9242b5459ee0768bb
https://doi.org/10.1200/jco.22.01826
https://doi.org/10.1200/jco.22.01826
Autor:
Mackenzie W. Sullivan, Allison Gockley, Ying-Chun Lo, Lynette M. Sholl, Suzanne George, Colleen Feltmate
Publikováno v:
Gynecologic Oncology Reports, Vol 33, Iss , Pp 100613- (2020)
Externí odkaz:
https://doaj.org/article/1cf6f35048124d18ab68c1ac83a55752
Autor:
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Publikováno v:
Clinical Cancer Research. 29:1412-1422
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::099b140efab4ae35818a5a0c4c867b08
https://doi.org/10.1158/1078-0432.ccr-22-3334
https://doi.org/10.1158/1078-0432.ccr-22-3334